Archive for the ‘bioengineering’ category: Page 131
Aug 13, 2019
Platform for lab-grown heart cells lets researchers examine functional effects of drugs
Posted by Paul Battista in categories: bioengineering, biotech/medical, computing
Animal models provide benefits for biomedical research, but translating such findings to human physiology can be difficult. The human heart’s energy needs and functions are difficult to reproduce in other animals, such as mice and rats. One new system looks to circumvent these issues and provide a functional view of how different treatments can help ailing cells in the heart following oxygen and nutrient deprivations.
Researchers have unveiled a new silicon chip that holds human lab-grown heart muscle cells for assessing the effectiveness of new drugs. The system includes heart cells, called cardiomyocytes, patterned on the chip with electrodes that can both stimulate and measure electrical activity within the cells. The researchers discuss their work in this week’s APL Bioengineering.
These capabilities provide a way for determining how the restriction of blood supply, a dangerous state known as ischemia, changes a heart’s conduction velocity, beat frequency and important electrical intervals associated with heart function.
Aug 12, 2019
5 Reasons Jeff Bezos Should Bet Big On Synthetic Biology
Posted by Klaus Baldauf in categories: bioengineering, biological, space
Jeff Bezos speaking at the grand opening of the Amazon Spheres, a new glass dome conservatory at the company’s Seattle headquarters. If going to space is vital for a thriving civilization, then we had better develop the synthetic biology tools and tech to enable it.
Aug 12, 2019
Multiplexed genome engineering
Posted by Genevieve Klien in categories: bioengineering, biotech/medical, genetics
The ability to modify multiple genetic elements simultaneously would help to elucidate and control the gene interactions and networks underlying complex cellular functions. However, current genome engineering technologies are limited in both the number and the type of perturbations that can be performed simultaneously. Here, we demonstrate that both Cas12a and a clustered regularly interspaced short palindromic repeat (CRISPR) array can be encoded in a single transcript by adding a stabilizer tertiary RNA structure. By leveraging this system, we illustrate constitutive, conditional, inducible, orthogonal and multiplexed genome engineering of endogenous targets using up to 25 individual CRISPR RNAs delivered on a single plasmid. Our method provides a powerful platform to investigate and orchestrate the sophisticated genetic programs underlying complex cell behaviors.
Aug 10, 2019
Don’t change your DNA at home, says America’s first CRISPR law
Posted by Gerard Bain in categories: bioengineering, biotech/medical, genetics, law
A California “human biohacking” bill calls for warnings on do-it-yourself genetic-engineering kits.
Aug 9, 2019
China approves ethics advisory group after CRISPR-babies scandal
Posted by Genevieve Klien in categories: bioengineering, biotech/medical, ethics
Bioethicists hope a national committee will help close loopholes in the country’s biomedical ethics regulations.
Aug 9, 2019
Bill Faloon, Director / Co-Founder of Life Extension Foundation — ideaXme Show — Ira Pastor
Posted by Ira S. Pastor in categories: aging, bioengineering, biotech/medical, business, genetics, health, life extension, neuroscience, posthumanism, transhumanism
Aug 8, 2019
CRISPR Gene Editing Is Being Tested In Human Patients And Scientists Admit They Do Not Know “What The Long-Term Effects Of Man-Made Edits To The Human Genome Might Have”
Posted by Genevieve Klien in categories: bioengineering, biotech/medical, entertainment
Scientists agree that CRISPR holds great promise in giving researchers unprecedented power to snip out abnormal stretches of DNA, But there are still significant questions about how safe and effective CRISPR gene editing will be once it’s unleashed in the human body. CRISPR works well enough in the lab, in a dish of human cells, but as with any technology, there are glitches. Some studies have shown that the gene editing goes awry once in a while, splicing incorrect places in the genome. Then there is the bigger question of what longer term, unanticipated effects man-made edits to the human genome might have… (READ MORE)
Aug 8, 2019
Bill Faloon: A Life Long Quest To Reverse Human Aging!
Posted by Paul Battista in categories: bioengineering, biotech/medical, cryonics, education, food, life extension, quantum physics, transhumanism
Ira Pastor, ideaXme longevity and aging Ambassador and Founder of Bioquark interviews Bill Faloon, Director and Co-Founder, Life Extension Foundation and Founder of The Church Of Perpetual Life.
Ira Pastor Comments:
Continue reading “Bill Faloon: A Life Long Quest To Reverse Human Aging!” »
Aug 6, 2019
CRISPR Gene Editing Is Being Tested in Human Patients. Here’s What You Need to Know
Posted by Genevieve Klien in categories: bioengineering, biotech/medical, genetics
The trial is just one of a few underway to test the powerful CRISPR technology around the world. One of the most promising, for example, is studying whether gene editing can treat, and effectively cure, blood disorders such as beta thalassemia and sickle cell anemia.
In beta thalassemia, the hemoglobin part of red blood cells, which is supposed to pick up oxygen from the lungs and distribute it to the cells in the rest of the body, doesn’t work properly. Patients need to be transfused with donors blood regularly, and even with these transfusions, complications can occur if the dose isn’t right and iron levels in the blood cells spike, which can lead to organ damage and even death. In sickle cell disease, a mutation in the gene that makes hemoglobin causes the red blood cells to collapse into a sickle shape, which makes it more difficult for the cells to flow smoothly through the body’s arteries and veins. Blockages caused by the misshapen blood cells can lead to severe pain and strokes.
The biotech company CRISPR Therapeutics, founded by one of the technology’s co-developers, has engineered a solution to treat both conditions that relies on genetic modifications connected to the production of fetal hemoglobin. Normally fetal hemoglobin, which provides the developing fetus with oxygen via the blood while in utero, is shut off about six months after birth, and genes for adult hemoglobin are turned on. While it’s not clear why adult hemoglobin replaces the fetal version, researchers say that they have not seen any significant differences between the two types when it comes to the ability to transport oxygen to the body’s cells. However, since the genes for adult hemoglobin don’t produce healthy red blood cells in people with beta thalassemia and sickle cell disease, one treatment strategy is to introduce genetic changes that turn on fetal hemoglobin again.